Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Stock Information for Cybin Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cybin Inc.

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
Cybin to Participate in the Jefferies Global Healthcare Conference in London
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025
Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Cybin to Participate at the 2025 Milken Institute Future of Health Summit
Cybin Announces Closing of $175 Million Registered Direct Offering
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.